share_log

康哲藥業:翌日披露報表

CMS: Next Day Disclosure Return

香港交易所 ·  Apr 12 07:28
Summary by Moomoo AI
康哲藥業控股有限公司(CMS)於2024年4月2日至12日進行了一系列股份購回活動,但並未註銷這些股份。根據香港聯合交易所有限公司證券上市規則,公司必須披露這些變動。在這段期間內,公司共購回了9,300,000股普通股,佔其已發行股份的0.3793%。最後一次購回發生在2024年4月12日,當天購回了1,050,000股,每股價格介於HKD 7.21至HKD 7.35之間,總計花費了HKD 7,642,680。公司確認所有購回活動均獲董事會批准,並符合相關上市規則的要求。
康哲藥業控股有限公司(CMS)於2024年4月2日至12日進行了一系列股份購回活動,但並未註銷這些股份。根據香港聯合交易所有限公司證券上市規則,公司必須披露這些變動。在這段期間內,公司共購回了9,300,000股普通股,佔其已發行股份的0.3793%。最後一次購回發生在2024年4月12日,當天購回了1,050,000股,每股價格介於HKD 7.21至HKD 7.35之間,總計花費了HKD 7,642,680。公司確認所有購回活動均獲董事會批准,並符合相關上市規則的要求。
Conge Pharmaceuticals Holdings Limited (CMS) conducted a series of share repurchases from April 2 to 12, 2024, but did not write them off. Under the Listing Rules of the Hong Kong Stock Exchange Limited, companies are required to disclose these changes. During this period, the company repurchased a total of 9,300,000 shares of common stock, representing 0.3793% of its issued shares. The last repurchase took place on April 12, 2024, and 1,050,000 shares were repurchased on the same day, priced between HKD 7.21 and HKD 7.35 for a total cost of HKD 7,642,680. The Company confirms that all repurchases have been approved by the Board of Directors and meet the requirements of the relevant Listing Rules.
Conge Pharmaceuticals Holdings Limited (CMS) conducted a series of share repurchases from April 2 to 12, 2024, but did not write them off. Under the Listing Rules of the Hong Kong Stock Exchange Limited, companies are required to disclose these changes. During this period, the company repurchased a total of 9,300,000 shares of common stock, representing 0.3793% of its issued shares. The last repurchase took place on April 12, 2024, and 1,050,000 shares were repurchased on the same day, priced between HKD 7.21 and HKD 7.35 for a total cost of HKD 7,642,680. The Company confirms that all repurchases have been approved by the Board of Directors and meet the requirements of the relevant Listing Rules.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more